ERBB2 and breast cancer: Consequently, in August 2022, the US Food and Drug Administration approved trastuzumab T-DXd for the treatment of patients with HER2-low metastatic BC, adding this new treatment to the National Comprehensive Cancer Network Guidelines for this subgroup of patients [66,67,68,69].